Q Biomed Inc.
501 Madison Ave, 14th Floor
63 articles with Q Biomed Inc.
Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States
Jubilant Radiopharma to Distribute Strontium-89 Chloride Injection USP Throughout the United States
Under terms of the global royalty agreement, Q BioMed will assume immediate ownership of the pain asset, as well as an abbreviated new drug application for the treatment.
Q BioMed Announces Legal Settlement and Acquisition of FDA Approved Non-Opioid Metastatic Cancer Pain Drug
Q BioMed Inc. (OTCQB: QBIO), is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89 Chloride USP
Q Biomed and Collaborator Chemveda Life Sciences Enter Agreement for Synthesis and Manufacturing of Liver Cancer Chemotherapeutic
Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines
Q BioMed and Collaborator Chemveda Life Sciences Announce Potential Chemotherapeutic Breakthrough in Liver Cancer
Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the treatment of liver cancer
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today announced advancements on several fronts for its key asset, QBM-001, in the treatment of pediatric minimally verbal autism (PMVA), a rare autism spectrum disorder (ASD) for which no effective treatment currently exists.
Q BioMed Inc. invests strategic capital into undervalued biotech assets and collaborates with passionate scientists to advance promising therapeutics for the benefit of patients in need.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the discovery of two novel biomarkers for pediatric nonverbal autism, identified in a subset of children with Autism Spectrum Disorder (ASD).
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced that it has released a new Company Spotlight article on high profile biomedical company Q BioMed Inc..
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Company Spotlight article on high profile biomedical company Q Biomed Inc.
Q BioMed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression from Washington University
Groundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression
Q BioMed Inc., is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company.
Q BioMed Inc. announced the Company's CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City.
Q BioMed Technology Partner Mannin Research Enters Into Collaboration With McMaster University for Glaucoma Drug Candidate MAN-01
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.
1/18/2019Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.
Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001
Strategy and Clinical Trial Design Specialist Provides Expertise for the Clinical Trial Design and Regulatory Requirements of QBM-001
Company Highlights Recent Achievements and Looks Toward an Active Milestone Rich 2019
Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children
Q Biomed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018